Klassische Panarteriitis nodosa inklusive Hepatitis B und Hepatitis C assoziierte Formen, Kawasaki-Syndrom

T. Witte

doi:10.1055/s-0032-1323827

Aktuelle Rheumatologie, Inhaltsverzeichnis

Aktuelle Rheumatologie 2013; 38(05): 288-293
DOI: 10.1055/s-0032-1323827

Übersichtsarbeit

Klassische Panarteriitis nodosa inklusive Hepatitis B und Hepatitis C assoziierte Formen, Kawasaki-Syndrom

Classic Polyarteritis Nodosa Including Hepatitis B- and Hepatits C-associated Forms and Kawasaki Syndrome

T. Witte

¹Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover, Hannover

› Institutsangaben

Abstract

Zusammenfassung

Die klassische Panarteriitis nodosa und das Kawasaki-Syndrom sind Vaskulitiden mit Beteiligung mittelgroßer Arterien. Während das Kawasaki-Syndrom fast nur bei Kindern auftritt, liegt der Altersgipfel der klassischen Panarteriitis nodosa zwischen 50 und 60 Jahren. In diesem Übersichtsartikel werden die Erkenntnisse zur Pathophysiologie, Diagnostik und Therapie dieser Vaskulitiden erläutert.

Abstract

Classic polyarteritis nodosa and Kawasaki syndrome are vasculitic disorders of medium-sized arteries. Kawasaki syndrome is almost exclusively affecting children. The peak incidence of polyarteritis nodosa is at an age between 50 and 60 years. In this review, the pathophysiology, diagnostic procedures and treatment of the vasculitides are discussed.

Schlüsselwörter

Kawasaki-Syndrom - klassische Panarteriitis nodosa - PAN

Key words

Kawasaki syndrome - classic polyarteritis nodosa - PAN

Volltext

Referenzen

Literatur
1 Kussmaul A, Maier R. Über eine bisher nicht beschriebene eigenthümliche Arterienerkrankung (Periarteriitis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. Dtsch Arch Klin Med 1866; 1: 484-518
2 Watts RA, Gonzalez-Gay MA, Lane SE et al. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001; 60: 170-172
3 Guillevin L, Mahr A, Callard P et al. French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84: 313-322
4 Ramos-Casals M, Muñoz S, Medina F et al. HISPAMEC Study Group. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36: 1442-1448
5 Finkel TH, Török TJ, Ferguson PJ et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent?. Lancet 1994; 343: 1255-1258
6 Carpenter MT, West SG. Polyarteritis nodosa in hairy cell leukemia: treatment with interferon-alpha. J Rheumatol 1994; 21: 1150-1152
7 Mason JC, Cowie MR, Davies KA et al. Familial polyarteritis nodosa. Arthritis Rheum 1994; 37: 1249-1253
8 Sonomoto K, Miyamura T, Watanabe H et al. A case of polyarteritis nodosa successfully treated by rituximab. Nihon Rinsho Meneki Gakkai Kaishi 2008; 31: 119-123
9 Al-Bishri J, le Riche N, Pope JE. Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 2005; 32: 1371-1373
10 Murakami M, Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol 2011; 23: 273-277
11 Tervaert JW, Kallenberg C. Neurologic manifestations of systemic vasculitides. Rheum Dis Clin North Am 1993; 19: 913-940
12 Fort JG, Griffin R, Tahmoush A et al. Muscle involvement in polyarteritis nodosa: report of a patient presenting clinically as polymyositis and review of the literature. J Rheumatol 1994; 21: 945-948
13 Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep 2004; 6: 203-211
14 Ozaki K, Miyayama S, Ushiogi Y et al. Renal involvement of polyarteritis nodosa: CT and MR findings. Abdom Imaging 2009; 34: 265-270
15 Ozen S, Besbas N, Saatci U et al. Diagnostic criteria for polyarteritis nodosa in childhood. J Pediatr 1992; 120: 206-209
16 Lightfoot Jr RW, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990 33. 1088-1093
17 Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192
18 Guillevin L, Lhote F, Gayraud M et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine 1996; 75: 17-28
19 Ribi C, Cohen P, Pagnoux C et al. French Vasculitis Study Group. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 2010; 62: 1186-1197
20 Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979; 67: 941-947
21 Dillon MJ, Eleftheriou D, Brogan PA. Medium-size-vessel vasculitis. Pediatr Nephrol 2010; 25: 1641-1652
22 Guillevin L, Lhote F, Cohen P et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638-1645
23 Eleftheriou D, Melo M, Marks SD et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford) 2009; 48: 978-986
24 Guillevin L, Merrouche Y, Gayraud M et al. Periarteritis nodosa related to hepatitis B virus. Determination of a new therapeutic strategy: 13 cases. Presse Med 1988; 17: 1522-1526
25 Avşar E, Savaş B, Tözün N et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy. J Hepatol 1998; 28: 525-526
26 Gayraud M, Guillevin L, le Toumelin P et al. French Vasculitis Study Group. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666-675
27 Bourgarit A, Le Toumelin P, Pagnoux C et al. French Vasculitis Study Group. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005; 84: 323-330
28 Nakamura Y, Yashiro M, Uehara R et al. Epidemiologic features of kawasaki disease in Japan: results of the 2009–2010 nationwide survey. J Epidemiol 2012; 22: 216-221
29 Harnden A, Mayon-White R, Perera R et al. Kawasaki disease in England: ethnicity, deprivation, and respiratory pathogens. Pediatr Infect Dis J. 2009; 28: 21-24
30 Burgner D, Davila S, Breunis WB et al. International Kawasaki Disease Genetics Consortium. A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. PLoS Genet 2009; 5: e1000319
31 Onouchi Y, Ozaki K, Burns JC et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 2012; 44: 517-521
32 Brogan PA. What’s new in the aetiopathogenesis of vasculitis?. Pediatr Nephrol 2007; 22: 1083-1094
33 Matsubara K, Fukaya T, Miwa K et al. Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease. Clin Exp Immunol 2006; 143: 427-434
34 Rowley AH, Shulman ST. Kawasaki syndrome. Clin Microbiol Rev. 1998; 11: 405-414
35 Tanaka H, Waga S, Tateyama T et al. Acute tubulointerstitial nephritis following intravenous immunoglobulin therapy in a male infant with minimal-change nephrotic syndrome. Tohoku J Exp Med 1999; 189: 155-161
36 Newburger JW, Takahashi M, Gerber MA et al. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114: 1708-1733
37 Ayusawa M, Sonobe T, Uemura S et al. Kawasaki Disease Research Committee. Revision of diagnostic guidelines for Kawasaki disease (the 5^th revised edition). Pediatr Int 2005; 47: 232-234
38 Council on Cardiovascular Disease in the Young; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; American Heart Association . Diagnostic guidelines for Kawasaki disease. Circulation. 2001. 103. 335-336
39 Ozen S, Ruperto N, Dillon MJ et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65: 936-941
40 Durongpisitkul K, Gururaj VJ, Park JM et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96: 1057-1061
41 Brogan PA, Bose A, Burgner D et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child 2002; 86: 286-290
42 Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997; 131: 888-893
43 Newburger JW, Takahashi M, Beiser AS et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633-1639
44 Newburger JW, Sleeper LA, McCrindle BW et al Pediatric Heart Network Investigators. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356: 663-675
45 Kobayashi T, Saji T, Otani T et al. RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379: 1613-1620
46 Mori M, Imagawa T, Hara R et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol 2012; 39: 864-867
47 Nakamura Y, Aso E, Yashiro M et al. Mortality among persons with a history of kawasaki disease in Japan: mortality among males with cardiac sequelae is significantly higher than that of the general population. Circ J. 2008; 72: 134-138
48 Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986; 108: 923-927
49 Hirata S, Nakamura Y, Yanagawa H. Incidence rate of recurrent Kawasaki disease and related risk factors: from the results of nationwide surveys of Kawasaki disease in Japan. Acta Paediatr 2001; 90: 40-44